methotrexate

P1, N=29, Not yet recruiting, Children's Oncology Group

Therapeutic management followed an early, aggressive strategy, frequently utilizing cyclophosphamide (45.8%) and methotrexate (37.5%), with Janus kinase (JAK) inhibitors or rituximab employed in refractory cases. The observed dissociation between low CK/CRP and elevated LDH underscores the necessity for a high index of suspicion, with LDH serving as a superior marker for disease activity. While ILD presents a significant risk, early and intensive multi-modal intervention may yield superior survival outcomes in European patients compared to the historical mortality rates reported in Asian cohorts.

Groups included a control group, a model group, a methotrexate positive control group [MTX(methotrexate), 10 μmol/L], and curcumin treatment groups at varying concentrations (10-100 μmol/L)... Curcumin (CUR) can effectively inhibit the inflammatory response of synovial fibroblasts by activating the expression of NRF2 and subsequently suppressing the cGAS-STING-NF-κB signaling pathway. This study provides a new molecular mechanism target for curcumin in the treatment of RA and offers a theoretical basis for the intervention of autoimmune diseases with natural products.

Six experimental studies using animal models were selected, which showed that agents such as doxorubicin, cisplatin, and methotrexate induce changes in domains such as memory, attention, and learning. These findings suggest that miRNAs play a central role in mediating the observed neurocognitive changes and may represent promising biomarkers and therapeutic targets to mitigate the effects of chemobrain. The study also highlights the need for future research integrating molecular and behavioral analyses to achieve more precise clinical applications.

CHT regimens usually mimic those used in osteosarcoma, including methotrexate-doxorubicin-cisplatin (MAP), doxorubicin-ifosfamide (AI), or doxorubicin-cisplatin (AP) - albeit with lower pathological response rates and substantial haematological toxicity. Emerging systemic treatment strategies were also described. Prospective data on the inhibition of mutant IDH1 indicate that olutasidenib (NCT03684811) can control the disease, but its activity in DCS is limited (median progression-free survival (PFS) of 1.5 months, 95% confidence interval (CI) 0.2-not reached (NR)).

The CIA model was established in DBA/1 mice, which were treated with anti-IL-33, methotrexate, or vehicle...IL-33 blockade effectively mitigates synovial inflammation and joint destruction by suppressing the proliferation, migration, and invasion of RA-FLSs while promoting their apoptosis. Targeting IL-33 may represent a promising strategy for the treatment of rheumatoid arthritis.

Given persistent cholestasis and bleeding risk, the patient underwent Roux-en-Y choledochojejunostomy for biliary decompression, followed by initiation of rituximab-cyclophosphamide-vincristine-doxorubicin-high-dose methotrexate/rituximab-ifosfamide-etoposide-high-dose cytarabine (R-CODOX-M/R-IVAC) with central nervous system prophylaxis...Ampullary BL should be considered in pediatric patients with obstructive jaundice and upper gastrointestinal bleeding. Surgical biliary decompression can stabilize cholestasis and facilitate timely multi-agent chemotherapy.

This is the first detailed ENNK cohort from Northeast India; patients referred to our center as refractory chronic sinusitis or granulomatous disease turned out to be ENNK. Practicing otorhinolaryngologists in Asia should include ENNK in differential diagnoses for early detection and improved outcomes.

Semi-quantitative histological scoring confirmed that LEES effectively limited articular structural damage without inducing the hepato-splenic toxicity associated with methotrexate. These findings indicate that LEES possesses multimodal immunomodulatory and analgesic actions with a highly favorable tolerability profile, supporting its further preclinical development as a potential adjunct or alternative to existing therapies.

In this work, we propose a novel dual-biosensor platform for TDM, designed to simultaneously detect multiple chemotherapeutic agents-cyclophosphamide, ifosfamide, etoposide, methotrexate, and 5-fluorouracil-for precision oncology. By integrating MWCNTs with cytochrome P450 enzymes (CYP3A4 and CYP2B6), our platform achieves enhanced electron transfer and substrate specificity, enabling sensitive and selective detection of the five chemotherapeutic drugs, individually and in combination, within clinically relevant ranges. Designed for portability and rapid analysis, this dual-biosensor platform enables real-time, cost-effective drug monitoring at the point-of-care, advancing personalized cancer treatment with greater precision and accessibility.

In a dose-dependent pattern, the two doses of L-Met significantly attenuated the cardiotoxic effect of MTX, with the higher dose being more effective. In conclusion, L-Met protected against MTX cardiotoxicity in a rat model via attenuating oxidative stress and inflammation, representing preliminary preclinical evidence that warrants further investigation.

Elevated TWEAK reflects psoriasis and PsA activity. Adalimumab and methotrexate reduce TWEAK alongside clinical improvement, supporting its potential as a biomarker for treatment monitoring. Key Points • Serum TWEAK levels were substantially elevated in psoriasis and psoriatic arthritis patients in comparison to controls. • TWEAK levels decreased following treatment with methotrexate and adalimumab. • Clinical improvement and disease activity scores were positively correlated with a decrease in TWEAK levels. • TWEAK may be a valuable biomarker for the monitoring of treatment response in psoriasis.